Effect of nirmatrelvir/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C.
<h4>Background</h4>Nirmatrelvir with ritonavir (Paxlovid) is indicated for patients with Coronavirus Disease 2019 (COVID-19) who are at risk for progression to severe disease due to the presence of one or more risk factors. Millions of treatment courses have been prescribed in the United...
Saved in:
Main Authors: | Abhishek Bhatia, Alexander J Preiss, Xuya Xiao, M Daniel Brannock, G Caleb Alexander, Robert F Chew, Hannah Davis, Megan Fitzgerald, Elaine Hill, Elizabeth P Kelly, Hemalkumar B Mehta, Charisse Madlock-Brown, Kenneth J Wilkins, Christopher G Chute, Melissa Haendel, Richard Moffitt, Emily R Pfaff, N3C Consortium |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2025-01-01
|
Series: | PLoS Medicine |
Online Access: | https://doi.org/10.1371/journal.pmed.1004493 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study
by: Haiyu Wang, et al.
Published: (2025-01-01) -
Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes
by: Guanyue Su, et al.
Published: (2025-02-01) -
Real-world cost-effectiveness of nirmatrelvir-ritonavir as treatment for SARS-CoV-2 infection in the Belgian setting with omicron variant
by: Sophie Marbaix, et al.
Published: (2025-02-01) -
Stability indicating RP-HPLC technique for simultaneous estimation of nirmatrelvir and ritonavir in their new copackaged dosage form for COVID-19 treatment
by: Mohamed G. Yassin, et al.
Published: (2025-01-01) -
Simultaneous determination of nirmatrelvir, ritonavir, and beta-D-N4-hydroxycytidine in human plasma and epithelial lining fluid using LC-MS/MS and its clinical application to compare rates of achieving effective concentrations
by: Wenjing Zhang, et al.
Published: (2025-01-01)